Full Year 2013 Morphosys AG Earnings Conference Call Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other Feb 28 Calls
Today's Calls
Call Details
Full Year 2013 Morphosys AG Earnings Conference Call
Scheduled to start Fri, Feb 28, 2014, 8:00 am Eastern

-- this event is ongoing now--
Listen to the ongoing live event audio stream

About Morphosys AG (XETRA:MOR.DE)
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of antibodies for therapeutic, as well as research and diagnostic applications. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 70 human antibody drug candidates primarily for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease. MorphoSys AG operates therapeutic develops programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary drugs based on therapeutic antibodies using the company’s technology. The company’s proprietary programs comprise MOR103, an antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis, as well as other proprietary clinical programs, including MOR208 and MOR202 for the treatment of cancer. It has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; and Celgene Corporation to advance CD38 Cancer Program MOR202 for Multiple Myeloma. The company was founded in 1992 and is headquartered in Martinsried, Germany.

More Info: Quote | News | Profile

Copyright © 2014 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2014 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.